Antoine Papiernik, Sofinnova managing director
Sofinnova Partners stays focused on late-stage deals with a new, $540M crossover fund
One of Europe’s most high-profile biopharma investors is getting $540 million to invest in new crossover deals for late-stage companies.
The Paris-based VC says the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
